Pluristem is a regenerative medicine company with a focus on novel biological products to treat severe medical conditions such as COVID-19. It has signed a venture debt loan of €50 million with the European Investment Bank and is the first Israeli-European business to benefit from a guarantee from the European Fund for Strategic Investment. The financing will support the company’s research and development in the EU through its German subsidiary Pluristem GmbH.
More on the Press release.
